About Renibus Therapeutics
Renibus Therapeutics is a Healthcare company based in Southlake (United States) founded in 2013 by Jeff Keyser and Alvaro F Guillem. Therapeutics for kidney diseases are developed by Renibus Therapeutics. Renibus Therapeutics has raised $153.52 million across 4 funding rounds from investors including Oxford Finance. Its chief executive, as recorded, is Alvaro F Guillem. Renibus Therapeutics offers products and services including RBT-1 and Veverimer. Its focus areas include Life Sciences, Nephrology, Drugs and Metabolic Diseases. Its legal entity is Renibus Therapeutics Inc. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Renibus Therapeutics was founded in 2013 and is based in Southlake, United States. Focus is placed on the biotechnology sector, where therapeutics for kidney-related conditions are developed. Key products include RBT-1, aimed at preventing acute kidney injury, RBT-2 for treating chronic kidney disease, RBT-3 addressing iron deficiency anemia, and RBT-9 targeting enveloped viruses. The company is led by co-founders Jeff Keyser and Alvaro F. Guillem, who serves as CEO.
- Headquarters Southlake, United States
- Founders Jeff Keyser, Alvaro F Guillem
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website renibus.com
- Social LinkedIn X
- Legal Name Renibus Therapeutics Inc.
- Total Equity Funding$153.52M (USD)
in 4 rounds
- Latest Funding Round$95.91M (USD), Series B
May 2023
- Investors
Products & Services of Renibus Therapeutics
Renibus Therapeutics offers a comprehensive portfolio of products and services, including RBT-1 and Veverimer.
IV drug to reduce risks after cardiac surgery.
Oral treatment for orphan diseases with unmet needs.
Funding Insights of Renibus Therapeutics
Renibus Therapeutics has successfully raised a total of $153.52M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $95.91 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $153.52M
- Total Rounds 4
- Last Round Series B — $95.91M
- First Round $34.61M
(Feb 2022)
- Investors Count 1
All 4 funding rounds of Renibus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $95.91M | Series B | – | – | – |
| Aug 2022 | $10M | Debt – Conventional | – | – | |
| Jul 2022 | $23M | Series A | – | – | – |
| Feb 2022 | $34.61M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Renibus Therapeutics
Renibus Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States |
Investor details for Renibus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Renibus Therapeutics
35 people are tracked at Renibus Therapeutics (18 in leadership, 14 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Jeff Keyser | Co-Founder | Leadership |
Alvaro F Guillem | Co-Founder & CEO | Leadership |
Jamie A. Donadio | CFO | Leadership |
Nels Bergmark | Director Of Finance And Human Resources | Leadership |
Mark Nuttall | Vice President of Quality Assurance | Leadership |
Richard Lawson | Senior Director Quality Assurance | Leadership |
D. Jeff Keyser | President & COO | Leadership |
Bhupinder Singh | Chief Medical Officer | Leadership |
Norma Schafer | Vice President Regulatory Affairs | Leadership |
Wendy Render, PhD | Senior Director, Field Medical Affairs | Leadership |
Maureen Early | VP Commercial | Leadership |
Sheena Perez | Director Of CMC | Leadership |
Jack Reed | Sr. Director of Operations at Renibus Therapeutics | Leadership |
Fiona Stavros | Sr. VP Pre-Clinical Affairs | Leadership |
Dina Lynch | Vice President, Market Access And Reimbursement | Leadership |
Stewart Turner | Vice President Of Clinical Operations And Medical Affairs | Leadership |
Stacey Ruiz | Vice President, Clinical Development | Leadership |
Ayla Rasmussen, MSc | Associate Director, Clinical Operations | Leadership |
Ravi Thadhani, | Scientific Advisor | Board & advisors |
Jean-Claude Tardif | Scientific Advisor | Board & advisors |
15 more people are available in the full profile.
Complete people profiles for Renibus Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Renibus Therapeutics
3 dated milestones of Renibus Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Renibus Therapeutics is founded.
- Funding First funding round of $34.6M.
- Funding Latest funding round, Series B, of $95.9M.
Competitors of Renibus Therapeutics
Renibus Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Renibus Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Renibus Therapeutics
The website of Renibus Therapeutics (renibus.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 6.2% vs previous month
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Renibus Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renibus Therapeutics
Complete news archive for Renibus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renibus Therapeutics
Renibus Therapeutics was founded in 2013 and raised its 1st funding round 9 years after it was founded.
Renibus Therapeutics is headquartered in Southlake, United States. It is registered at Southlake, Texas, United States.
Alvaro F Guillem is the CEO of Renibus Therapeutics, as recorded in our data. They have also founded this company.
Renibus Therapeutics is a funded company, having raised a total of $153.52M across 4 funding rounds to date. The company's 1st funding round was a Series A of $34.61M, raised on Feb 2022.
Renibus Therapeutics was founded in 2013 and is based in Southlake, United States. Focus is placed on the biotechnology sector, where therapeutics for kidney-related conditions are developed. Key products include RBT-1, aimed at preventing acute kidney injury, RBT-2 for treating chronic kidney disease, RBT-3 addressing iron deficiency anemia, and RBT-9 targeting enveloped viruses. The company is led by co-founders Jeff Keyser and Alvaro F. Guillem, who serves as CEO.
Renibus Therapeutics's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Renibus Therapeutics offers RBT-1 and Veverimer.
Renibus Therapeutics has 1 investor. Key investors include Oxford Finance.
Renibus Therapeutics operates through Renibus Therapeutics Inc..